Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Chemistry
Emerging Technology
Immunoassays
Molecular Diagnostics
Pathology & AI
Gene expression
Independent directors of 23andMe resign
By
LabPulse.com staff writers
The seven independent directors of genetic testing company 23andMe resigned on September 17, saying they had not yet received a satisfactory take-private proposal from CEO Anne Wojcicki five months after she made the offer.
September 18, 2024
Nightingale Health, 23andMe partner on blood panel program
By
LabPulse.com staff writers
Preventive health and risk-prediction company Nightingale Health and 23andMe have announced that they are joining up to offer a blood metabolomics panel to a group of 23andMe’s premium members through Nightingale’s Remote Health Check.
July 2, 2024
Applied DNA, GenXys partner on pharmacogenomic test
By
LabPulse.com staff writers
Applied DNA Sciences announced that its Applied DNA Clinical Labs molecular diagnostics subsidiary will use GenXys Health Care Systems' clinical decision support software for interpretation and reporting in its TR8 pharmacogenomic (TR8 PGx) test.
June 18, 2024
Molecular diagnostic test study continues EET benefit assessment
By
Liz Carey
A molecular oncology gene expression profiling (GEP) test for breast cancer biomarkers may influence extended endocrine therapy (EET) treatment decisions, according to an impact study.
April 2, 2024
MIT team develops genome-editing approach for cancer mutation screening
By
Matt Limb
Scientists say they have developed a method to screen cancer-associated genetic mutations more easily and quickly than any existing approach.
March 22, 2024
Weill Cornell study may support new prognostic test for prostate tumor spread
By
LabPulse.com staff writers
Scientists working in the department of pathology and laboratory medicine at Weill Cornell Medicine have found that certain noncancerous cells may be useful for assessing prostate tumors and their potential to spread.
January 16, 2024
Polygenic risk score tests don’t meet expectations, U.K. study shows
By
Matt Limb
Polygenic risk scores “perform poorly in screening and prediction of common disease,” failing to identify nearly 90% of patients who develop disease, according to a U.K. study.
October 26, 2023
Polygenic risk scores from multi-ancestry GWASs more accurate in diverse groups: Study
By
LabPulse.com staff writers
Polygenic risk scores (PRS) derived from multi-ancestry genome-wide association studies (GWASs) outperform PRSs based on single-ancestry GWASs in underrepresented populations, new research shows.
September 21, 2023
Castle Biosciences Pittsburgh lab receives N.Y. state permit
By
LabPulse.com staff writers
Castle Biosciences has received a clinical laboratory permit from the New York State Department of Health for its Pittsburgh laboratory.
September 13, 2023
Gene expression test may improve diagnosis of febrile childhood diseases
By
Matt Limb
A simple blood test based on patterns of gene expression could radically improve and speed up the diagnosis of febrile childhood diseases, say researchers.
August 30, 2023
Gene-specific approach recommended for variant pathogenicity prediction
By
Matt Limb
A research team investigated the efficacy of gene-specific supervised machine learning in predicting the pathogenicity of rare BRCA1/2 missense variants compared to the disease-specific approach.
August 22, 2023
CareDx lands Medicare coverage for heart transplant surveillance testing
By
Nick Paul Taylor
The testing service, branded HeartCare, features AlloMap Heart and AlloSure Heart, both of which have individual Medicare coverage.
August 9, 2023
Page 1 of 4
Next Page
